Lena Haeberle1, Andrea Cacciato Insilla2, Anne-Christine Kapp3, Katja Steiger4, Anna Melissa Schlitter4, Björn Konukiewitz4, Ihsan Ekin Demir5, Helmut Friess5, Irene Esposito1. 1. Institute of Pathology, Heinrich Heine University and University Hospital of Duesseldorf, Duesseldorf, Germany. 2. Department of Surgical, Medical, Molecular and Critical Care Pathology, University of Pisa, Pisa, Italy. 3. Department of Anesthesiology, University Hospital of Heidelberg, Heidelberg, Germany. 4. Institute of Pathology, Technical University of Munich, Munich, Germany. 5. Department of General Surgery, Klinikum Rechts der Isar, School of Medicine Technical University Munich, Munich, Germany.
Abstract
BACKGROUND: Tumor regression grading (TRG) based on histopathology is the main tool to assess therapy effects after neoadjuvant therapy (NAT) of pancreatic ductal adenocarcinoma (PDAC). However, reliable markers to distinguish therapy effects from pre-existing tumor features are lacking. The aim of this study was the characterization of PDAC after NAT, focusing on the stroma. MATERIAL AND METHODS: Tissue samples from patients resected for PDAC after NAT (n=27) were analyzed. TRG was assessed using the Royal North Shore (RNS) system. Stromal composition was evaluated by Movat's stain. Immunohistochemistry (IH) for Ki-67 and five previously established stroma markers (alpha-Crystallin B, alpha-Smooth muscle actin (alpha-SMA), Neurotrophin-3 (NT-3), SPARC and Tenascin C) was also performed. Results were compared with therapy-naïve PDACs (n=10). RESULTS: Most cases showed a moderate response (RNS 2; 74%), while 15% displayed a poor response (RNS 3), and 11% a good response (RNS 1). No complete response was observed. Poor regression was associated with mucin-rich stroma, while good regression was associated with collagen-rich stroma. Cases with poorer therapy response had significantly higher proliferation. Higher peritumoral staining intensity for alpha-SMA and Tenascin C also showed a trend towards an association with poor regression. CONCLUSIONS: Similar to the stroma in therapy-naïve PDAC, the stroma of PDAC after NAT is heterogeneous. Distinguishing between desmoplastic stroma and therapy-induced fibrosis by single markers is not possible. Movat's pentachrome stain, IH for Ki-67, and to some extent for Tenascin C and alpha-SMA, can help detect poor histopathological response to NAT.
BACKGROUND: Tumor regression grading (TRG) based on histopathology is the main tool to assess therapy effects after neoadjuvant therapy (NAT) of pancreatic ductal adenocarcinoma (PDAC). However, reliable markers to distinguish therapy effects from pre-existing tumor features are lacking. The aim of this study was the characterization of PDAC after NAT, focusing on the stroma. MATERIAL AND METHODS: Tissue samples from patients resected for PDAC after NAT (n=27) were analyzed. TRG was assessed using the Royal North Shore (RNS) system. Stromal composition was evaluated by Movat's stain. Immunohistochemistry (IH) for Ki-67 and five previously established stroma markers (alpha-Crystallin B, alpha-Smooth muscle actin (alpha-SMA), Neurotrophin-3 (NT-3), SPARC and Tenascin C) was also performed. Results were compared with therapy-naïve PDACs (n=10). RESULTS: Most cases showed a moderate response (RNS 2; 74%), while 15% displayed a poor response (RNS 3), and 11% a good response (RNS 1). No complete response was observed. Poor regression was associated with mucin-rich stroma, while good regression was associated with collagen-rich stroma. Cases with poorer therapy response had significantly higher proliferation. Higher peritumoral staining intensity for alpha-SMA and Tenascin C also showed a trend towards an association with poor regression. CONCLUSIONS: Similar to the stroma in therapy-naïve PDAC, the stroma of PDAC after NAT is heterogeneous. Distinguishing between desmoplastic stroma and therapy-induced fibrosis by single markers is not possible. Movat's pentachrome stain, IH for Ki-67, and to some extent for Tenascin C and alpha-SMA, can help detect poor histopathological response to NAT.
Authors: Irene Esposito; Jörg Kleeff; Frank Bergmann; Caroline Reiser; Esther Herpel; Helmut Friess; Peter Schirmacher; Markus W Büchler Journal: Ann Surg Oncol Date: 2008-03-20 Impact factor: 5.344
Authors: I Esposito; R Penzel; M Chaib-Harrireche; U Barcena; F Bergmann; S Riedl; H Kayed; N Giese; J Kleeff; H Friess; P Schirmacher Journal: J Pathol Date: 2006-04 Impact factor: 7.996
Authors: Deyali Chatterjee; Matthew H Katz; Asif Rashid; Gauri R Varadhachary; Robert A Wolff; Hua Wang; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Christopher Crane; Henry F Gomez; James L Abbruzzese; Jason B Fleming; Huamin Wang Journal: Cancer Date: 2011-10-25 Impact factor: 6.860
Authors: Lena Haeberle; Katja Steiger; Anna Melissa Schlitter; Sami Alexander Safi; Wolfram Trudo Knoefel; Mert Erkan; Irene Esposito Journal: Pancreatology Date: 2018-05-12 Impact factor: 3.996
Authors: Mert Erkan; Guido Adler; Minoti V Apte; Max G Bachem; Malte Buchholz; Sönke Detlefsen; Irene Esposito; Helmut Friess; Thomas M Gress; Hans-Joerg Habisch; Rosa F Hwang; Robert Jaster; Jörg Kleeff; Günter Klöppel; Claus Kordes; Craig D Logsdon; Atsushi Masamune; Christoph W Michalski; Junseo Oh; Phoebe A Phillips; Massimo Pinzani; Carolin Reiser-Erkan; Hidekazu Tsukamoto; Jeremy Wilson Journal: Gut Date: 2011-11-24 Impact factor: 23.059
Authors: Mashaal Dhir; Gautam K Malhotra; Davendra P S Sohal; Nicholas A Hein; Lynette M Smith; Eileen M O'Reilly; Nathan Bahary; Chandrakanth Are Journal: World J Surg Oncol Date: 2017-10-10 Impact factor: 2.754
Authors: M Redegalli; M Schiavo Lena; M Reni; C Doglioni; M G Cangi; C E Smart; M Mori; C Fiorino; P G Arcidiacono; G Balzano; M Falconi Journal: Ann Surg Oncol Date: 2022-03-01 Impact factor: 4.339
Authors: Damián Sánchez-Ramírez; Rafael Medrano-Guzmán; Fernando Candanedo-González; Jazmín De Anda-González; Luis Enrique García-Rios; Vadim Pérez-Koldenkova; Marcos Gutiérrez-de la Barrera; Sara Rodríguez-Enríquez; Marco Velasco-Velázquez; Silvia Cecilia Pacheco-Velázquez; Patricia Piña-Sánchez; Héctor Mayani; Alejandro Gómez-Delgado; Alberto Monroy-García; Ana Karen Martínez-Lara; Juan José Montesinos Journal: Eur J Histochem Date: 2022-02-17 Impact factor: 3.188
Authors: Marcella Massimini; Alessia Gloria; Mariarita Romanucci; Leonardo Della Salda; Lucia Di Francesco; Alberto Contri Journal: Vet Sci Date: 2022-09-15